ibandronic acid has been researched along with Kidney Failure, Chronic in 7 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 5 (71.43) | 29.6817 |
2010's | 2 (28.57) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Åsberg, A; Bollerslev, J; Dahle, DO; Godang, K; Hartmann, A; Kile, H; Pasch, A; Smerud, KT | 1 |
Bergner, R; Henrich, DM; Hoffmann, M; Uppenkamp, M | 1 |
Behets, GJ; D'Haese, P; Fischer, DC; Haffner, D; Jensen, C; Kundt, G; Rahn, A; Salewski, B | 1 |
Bals, G; Bergner, R; Henrich, D; Hoffmann, M; Lenz, T; Ullmann, M; Uppenkamp, M | 1 |
Daphnis, E; Karamitopoulou, E; Karkavitsas, N; Katsipi, I; Kyriazis, J; Stratigis, S; Stylianou, K | 1 |
De Broe, M; Ketteler, M; Persy, V | 1 |
Bauss, F; Geng, Z; Malluche, HH; Monier-Faugere, MC | 1 |
3 trial(s) available for ibandronic acid and Kidney Failure, Chronic
Article | Year |
---|---|
A rapid and sustained improvement of calcification propensity score (serum T
Topics: Bone Density Conservation Agents; Calcinosis; Diphosphonates; Female; Follow-Up Studies; Glomerular Filtration Rate; Graft Survival; Humans; Ibandronic Acid; Kidney Failure, Chronic; Kidney Function Tests; Kidney Transplantation; Male; Middle Aged; Norway; Prognosis; Propensity Score; Prospective Studies; Risk Factors | 2017 |
Tolerability of dose escalation of ibandronate in patients with multiple myeloma and end-stage renal disease: a case series.
Topics: Aged; Aged, 80 and over; Bone Density Conservation Agents; Diphosphonates; Dose-Response Relationship, Drug; Female; Humans; Ibandronic Acid; Kidney Failure, Chronic; Male; Middle Aged; Multiple Myeloma; Treatment Outcome | 2009 |
High bone-binding capacity of ibandronate in hemodialysis patients.
Topics: Adult; Aged; Bone and Bones; Bone Density; Bone Density Conservation Agents; Bone Resorption; Diphosphonates; Humans; Hyperparathyroidism, Secondary; Ibandronic Acid; Kidney Failure, Chronic; Middle Aged; Renal Dialysis; Treatment Outcome | 2005 |
4 other study(ies) available for ibandronic acid and Kidney Failure, Chronic
Article | Year |
---|---|
Ibandronate affects bone growth and mineralization in rats with normal and reduced renal function.
Topics: Animals; Bone Density Conservation Agents; Bone Development; Calcification, Physiologic; Calcium; Diphosphonates; Growth Plate; Ibandronic Acid; Kidney; Kidney Failure, Chronic; Male; Nephrectomy; Parathyroid Hormone; Phosphates; Rats; Rats, Sprague-Dawley | 2011 |
Parathyromatosis and the challenge of treatment.
Topics: Adult; Bone Density Conservation Agents; Diphosphonates; Disease Progression; Ergocalciferols; Female; Humans; Hypercalcemia; Hyperparathyroidism; Ibandronic Acid; Kidney Failure, Chronic; Renal Dialysis; Reoperation | 2006 |
Bisphosphonates prevent experimental vascular calcification: Treat the bone to cure the vessels?
Topics: Animals; Bone and Bones; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Bone Resorption; Calcinosis; Diphosphonates; Ibandronic Acid; Kidney; Kidney Failure, Chronic; Mice; Rats; Vascular Diseases | 2006 |
Short-term administration of the bisphosphonate ibandronate increases bone volume and prevents hyperparathyroid bone changes in mild experimental renal failure.
Topics: Alkaline Phosphatase; Animals; Bone and Bones; Bone Resorption; Calcium; Chronic Kidney Disease-Mineral and Bone Disorder; Creatinine; Diphosphonates; Female; Hyperparathyroidism, Secondary; Ibandronic Acid; Kidney Failure, Chronic; Osteocalcin; Parathyroid Hormone; Phosphorus; Rats; Rats, Sprague-Dawley | 2000 |